105 related articles for article (PubMed ID: 30648436)
21. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.
Shehata M; Schnabl S; Demirtas D; Hilgarth M; Hubmann R; Ponath E; Badrnya S; Lehner C; Hoelbl A; Duechler M; Gaiger A; Zielinski C; Schwarzmeier JD; Jaeger U
Blood; 2010 Oct; 116(14):2513-21. PubMed ID: 20576813
[TBL] [Abstract][Full Text] [Related]
22. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
25. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Liu TM; Ling Y; Woyach JA; Beckwith K; Yeh YY; Hertlein E; Zhang X; Lehman A; Awan F; Jones JA; Andritsos LA; Maddocks K; MacMurray J; Salunke SB; Chen CS; Phelps MA; Byrd JC; Johnson AJ
Blood; 2015 Jan; 125(2):284-95. PubMed ID: 25293770
[TBL] [Abstract][Full Text] [Related]
26. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
27. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
Shukla A; Shukla V; Joshi SS
Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
[TBL] [Abstract][Full Text] [Related]
28. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.
van Attekum MHA; Terpstra S; Slinger E; von Lindern M; Moerland PD; Jongejan A; Kater AP; Eldering E
Oncogene; 2017 Jun; 36(26):3651-3660. PubMed ID: 28192408
[TBL] [Abstract][Full Text] [Related]
29. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
30. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.
Shen Y; Crassini K; Fatima N; O'Dwyer M; O'Neill M; Christopherson RI; Mulligan SP; Best OG
Blood Adv; 2020 Oct; 4(20):5093-5106. PubMed ID: 33085757
[TBL] [Abstract][Full Text] [Related]
31. Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/MEK1/2 inhibitors in A549 human lung adenocarcinoma cells.
Kim CH; Kim MY; Moon JY; Hwang JW; Lee SY; Joo YM; Han SI; Park HG; Kang HS
Biochem Pharmacol; 2008 May; 75(9):1751-60. PubMed ID: 18358453
[TBL] [Abstract][Full Text] [Related]
32. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.
Zhuang J; Hawkins SF; Glenn MA; Lin K; Johnson GG; Carter A; Cawley JC; Pettitt AR
Haematologica; 2010 Jan; 95(1):110-8. PubMed ID: 19713228
[TBL] [Abstract][Full Text] [Related]
33. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract][Full Text] [Related]
34. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
35. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
36. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
Plate JM
Leuk Lymphoma; 2004 Aug; 45(8):1519-29. PubMed ID: 15370202
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Paiva C; Godbersen JC; Soderquist RS; Rowland T; Kilmarx S; Spurgeon SE; Brown JR; Srinivasa SP; Danilov AV
PLoS One; 2015; 10(11):e0143685. PubMed ID: 26606677
[TBL] [Abstract][Full Text] [Related]
39. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
Rosati E; Sabatini R; De Falco F; Del Papa B; Falzetti F; Di Ianni M; Cavalli L; Fettucciari K; Bartoli A; Screpanti I; Marconi P
Int J Cancer; 2013 Apr; 132(8):1940-53. PubMed ID: 23001755
[TBL] [Abstract][Full Text] [Related]
40. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
